Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin

Sun Kim(Seoul National University of Science and Technology), Yung‐Jue Bang(Seoul National University), Do Oh(Seoul National University), Yu Kyung Kim(Kyungpook National University), Dongsoon Lee(Seoul National University), Hyun-Soon Jong, Tae‐You Kim(Seoul National University Hospital), Seock‐Ah Im(Seoul National University)
International Journal of Oncology
January 1, 2008
10.3892/ijo.32.1.89
Cited by 118

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k